A carregar...
Baseline neutrophilia, derived neutrophil‐to‐lymphocyte ratio (dNLR), platelet‐to‐lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel
Nivolumab is a novel therapeutic option in NSCLC, associated with a significant survival gain compared with Docetaxel. However, predictive biomarkers are lacking. The presence of systemic inflammation has been correlated with poor outcome in many cancer types. We aimed to evaluate whether there is a...
Na minha lista:
| Publicado no: | J Cell Physiol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6767577/ https://ncbi.nlm.nih.gov/pubmed/29672849 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcp.26609 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|